BACKGROUND AND PURPOSE: Vasospasm-induced delayed cerebral ischemia remains a major source of morbidity in patients with aneurysmal subarachnoid hemorrhage (SAH). We hypothesized that activating innate neurovascular protective mechanisms by preconditioning (PC) may represent a novel therapeutic approach against SAH-induced vasospasm and neurological deficits and, secondarily, that the neurovascular protection it provides is mediated by endothelial nitric oxide synthase (eNOS). METHODS: Wild-type mice were subjected to hypoxic PC or normoxia followed 24 hours later by SAH. Neurological function was analyzed daily; vasospasm was assessed on post-surgery Day 2. Nitric oxide availability, eNOS expression, and eNOS activity were also assessed. In a separate experiment, wild-type and eNOS-null mice were subjected to hypoxic PC or normoxia followed by SAH and assessed for vasospasm and neurological deficits. RESULTS: PC nearly completely prevented SAH-induced vasospasm and neurological deficits. It also prevented SAH-induced reduction in nitric oxide availability and increased eNOS activity in mice with and without SAH. PC-induced protection against vasospasm and neurological deficits was lost in wild-type mice treated with the nitric oxide synthase inhibitor N(G)-nitro-l-arginine methyl ester and in eNOS-null mice. CONCLUSIONS: Endogenous protective mechanisms against vasospasm exist, are powerful, and can be induced by PC. eNOS-derived nitric oxide is a critical mediator of PC-induced neurovascular protection. These data provide strong "proof-of-principle" evidence that PC represents a promising new strategy to reduce vasospasm and delayed cerebral ischemia after SAH.
BACKGROUND AND PURPOSE:Vasospasm-induced delayed cerebral ischemia remains a major source of morbidity in patients with aneurysmal subarachnoid hemorrhage (SAH). We hypothesized that activating innate neurovascular protective mechanisms by preconditioning (PC) may represent a novel therapeutic approach against SAH-induced vasospasm and neurological deficits and, secondarily, that the neurovascular protection it provides is mediated by endothelial nitric oxide synthase (eNOS). METHODS: Wild-type mice were subjected to hypoxic PC or normoxia followed 24 hours later by SAH. Neurological function was analyzed daily; vasospasm was assessed on post-surgery Day 2. Nitric oxide availability, eNOS expression, and eNOS activity were also assessed. In a separate experiment, wild-type and eNOS-null mice were subjected to hypoxic PC or normoxia followed by SAH and assessed for vasospasm and neurological deficits. RESULTS:PC nearly completely prevented SAH-induced vasospasm and neurological deficits. It also prevented SAH-induced reduction in nitric oxide availability and increased eNOS activity in mice with and without SAH. PC-induced protection against vasospasm and neurological deficits was lost in wild-type mice treated with the nitric oxide synthase inhibitor N(G)-nitro-l-arginine methyl ester and in eNOS-null mice. CONCLUSIONS: Endogenous protective mechanisms against vasospasm exist, are powerful, and can be induced by PC. eNOS-derived nitric oxide is a critical mediator of PC-induced neurovascular protection. These data provide strong "proof-of-principle" evidence that PC represents a promising new strategy to reduce vasospasm and delayed cerebral ischemia after SAH.
Authors: Matthew J McGirt; John R Lynch; Augusto Parra; Huaxin Sheng; Robert D Pearlstein; Daniel T Laskowitz; Dale A Pelligrino; David S Warner Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: J M Gidday; A R Shah; R G Maceren; Q Wang; D A Pelligrino; D M Holtzman; T S Park Journal: J Cereb Blood Flow Metab Date: 1999-03 Impact factor: 6.200
Authors: John R Lynch; Haichen Wang; Brian Mace; Stephen Leinenweber; David S Warner; Ellen R Bennett; Michael P Vitek; Suzanne McKenna; Daniel T Laskowitz Journal: Exp Neurol Date: 2005-03 Impact factor: 5.330
Authors: Marcel A Kamp; Jasper H van Lieshout; Maxine Dibué-Adjei; Jasmin K Weber; Toni Schneider; Tanja Restin; Igor Fischer; Hans-Jakob Steiger Journal: Transl Stroke Res Date: 2017-01-30 Impact factor: 6.829
Authors: Eric Milner; Jacob C Holtzman; Stuart Friess; Richard E Hartman; David L Brody; Byung H Han; Gregory J Zipfel Journal: J Cereb Blood Flow Metab Date: 2014-06-18 Impact factor: 6.200
Authors: Rajat Dhar; Chad Washington; Michael Diringer; Allyson Zazulia; Hussain Jafri; Colin Derdeyn; Gregory Zipfel Journal: Neurocrit Care Date: 2016-10 Impact factor: 3.210